Skip to main content
Industry News
Gilead, Nurix to develop new therapies

Gilead Sciences agreed to give Nurix Therapeutics a $45 million upfront payment plus up to $2.3 billion in milestone payments in a deal that aims to develop and market new drugs for cancer and other undisclosed diseases.

Full Story: